Japan: Takeda to acquire GammaDelta Therapeutics

Japan-headquartered global biopharmaceutical company, Takeda Pharmaceutical is exercising of its option to acquire London-based GammaDelta Therapeutics, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. The acquisition gives Takeda GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in…

You must be a HMI Subscriber to view this content.

Subscribe Now »